[{"id":"edef415f-bd84-49a1-9a8c-360704fed600","acronym":"","url":"https://clinicaltrials.gov/study/NCT05786924","created_at":"2023-03-28T14:04:59.609Z","updated_at":"2024-07-02T16:35:02.207Z","phase":"Phase 1","brief_title":"A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers","source_id_and_acronym":"NCT05786924","lead_sponsor":"Black Diamond Therapeutics, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S241656"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-21"}]